A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence

Maroti, Marianne; Ulff, Eva; Lyth, Johan; Falkmer, Sture

doi:10.1684/ejd.2016.2845

Cited by 5 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, overall 5‐ and 10‐year survival rates were 59.8% and 38.9% in patients with relapse of melanoma (Salama et al, 2013). In line with other studies (Maroti et al, 2016; Salama et al, 2013), in our cohort patients with locoregional relapse had longer survival rate than those with haemato‐visceral disease.…”

Section: Discussionsupporting

confidence: 92%

“…Association between Breslow thickness and type of relapse is not clear. Some studies found no association (Adler et al, 2018), while others did (Maroti et al, 2016). Tejera‐Vaquerizo et al (2007) study reported that melanomas >4 mm in Breslow thickness had an increased risk of developing distant metastasis compared to locoregional disease.…”

Section: Discussionmentioning

confidence: 99%

“…In general, early stages have a lower risk of relapse. The hazard of relapse decreases as time passes from the moment of the diagnoses, although it does not reach 0 at any time (Maroti et al, 2016; Salama et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

“…About 10–30% of patients experience any type of relapse after initial treatment and they are more frequent in the first 2–3 years after initial diagnosis (Maroti et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Study of cutaneous melanoma recurrences after sentinel node biopsy: Patterns of dissemination and use of complementary test in follow‐up

et al. 2020

View full text Add to dashboard Cite

Objectives To investigate the patterns of melanoma recurrence in the local population, including factors that may influence in this event and timing of relapse, and to determine the mode of detection of them. Methods This is a retrospective cohort study of patients with melanoma who underwent sentinel lymph node biopsy at the Complejo Hospitalario de Navarra (Spain) from 2002 to 2012. The following data were collected of each patient: age, gender, date of diagnosis, location of melanoma, histological subtype, Breslow thickness, ulceration, mitosis, sentinel node status, AJCC 8th edition stage, site of first diagnosed metastasis, mode of relapse, date of first relapse and time of death. Results Of 308 patients, 30% people suffered metastasis. The mean follow‐up time was 68.63 months. 51.1% of relapses were locoregional and 48.9% haemato‐visceral. Sentinel node status was the only variable associated with higher risk of haemato‐visceral metastasis (p < 0.001). The mean time between diagnosis of melanoma and recurrence was 2.7 years. Most recurrences were detected by the patient himself or had any type of symptoms and were consequently selected for a complementary test. Conclusion It is important to follow‐up all patients with diagnosis of cutaneous melanoma, essentially during the first 5 years after diagnosis.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…About 10–30% of patients experience any type of relapse after initial treatment and they are more frequent in the first 2–3 years after initial diagnosis (Maroti et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Study of cutaneous melanoma recurrences after sentinel node biopsy: Patterns of dissemination and use of complementary test in follow‐up

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, B-Raf gene mutations are activated in 70% of human malignant melanomas [ 4 , 5 ]. Over the past decades, the incidence of malignant melanoma is steadily rising [ 6 ]. Although significant advances have been made in diagnosis and treatment of MM, therapy resistance and metastasis are still the major reasons for mortality of patients [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

UVA Irradiation Enhances Brusatol‐Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2‐Mediated Antioxidant Response

Wang

Shi

Bian

et al. 2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Brusatol (BR) is a potent inhibitor of Nrf2, a transcription factor that is highly expressed in cancer tissues and confers chemoresistance. UVA-generated reactive oxygen species (ROS) can damage both normal and cancer cells and may be of potential use in phototherapy. In order to provide an alternative method to treat the aggressive melanoma, we sought to investigate whether low-dose UVA with BR is more effective in eliminating melanoma cells than the respective single treatments. We found that BR combined with UVA led to inhibition of A375 melanoma cell proliferation by cell cycle arrest in the G1 phase and triggers cell apoptosis. Furthermore, inhibition of Nrf2 expression attenuated colony formation and tumor development from A375 cells in heterotopic mouse models. In addition, cotreatment of UVA and BR partially suppressed Nrf2 and its downstream target genes such as HO-1 along with the PI3K/AKT pathway. We propose that cotreatment increased ROS-induced cell cycle arrest and cellular apoptosis and inhibits melanoma growth by regulating the AKT-Nrf2 pathway in A375 cells which offers a possible therapeutic intervention strategy for the treatment of human melanoma.

show abstract

Understanding Mohs Micrographic Surgery

Tolkachjov¹,

Brodland

Coldiron

et al. 2017

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The incidence and diagnosis of cutaneous malignancies are steadily rising. In addition, with the aging population and increasing use of organ transplant and immunosuppressive medications, subsets of patients are now more susceptible to skin cancer. Mohs micrographic surgery (MMS) has become the standard of care for the treatment of high-risk nonmelanoma skin cancers and is increasingly used to treat melanoma. Mohs micrographic surgery has the highest cure rates, spares the maximal amount of normal tissue, and is cost-effective for the treatment of cutaneous malignancies. As in other medical fields, appropriate use criteria were developed for MMS and have become an evolving guideline for determining which patients and tumors are appropriate for referral to MMS. Patients with cutaneous malignancies often require multidisciplinary care. With the changing landscape of medicine and the rapidly increasing incidence of skin cancer, primary care providers and specialists who do not commonly manage cutaneous malignancies will need to have an understanding of MMS and its role in patient care. This review better familiarizes the medical community with the practice of MMS, its utilization and capabilities, differences from wide excision and vertical section pathology, and cost-effectiveness, and it guides practitioners in the process of appropriately evaluating and determining when patients with skin cancer might be appropriate candidates for MMS.

show abstract

A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence

Cited by 5 publications

References 29 publications

Study of cutaneous melanoma recurrences after sentinel node biopsy: Patterns of dissemination and use of complementary test in follow‐up

Study of cutaneous melanoma recurrences after sentinel node biopsy: Patterns of dissemination and use of complementary test in follow‐up

UVA Irradiation Enhances Brusatol‐Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2‐Mediated Antioxidant Response

Understanding Mohs Micrographic Surgery

Contact Info

Product

Resources

About